OBJECTIVE: Elevated plasma homocysteine concentration is considered to be an independent risk factor for cardiovascular disease. However, the mechanisms by which hyperhomocysteinemia are related to vascular disease are unclear. High-sensitivity C-reactive protein (CRP), a marker of inflammation, has been reported to be an independent predictor of future myocardial infarction among clinically healthy individuals. Interleukin (IL)-6 is a regulator of CRP and has a key role in initiation of inflammation. The aim of this study was to investigate whether individuals with increased plasma homocysteine concentrations have altered levels of serum CRP and IL-6. MATERIAL AND METHODS: Serum concentrations of CRP and IL-6 were measured in 39 individuals with hyperhomocysteinemia and in 39 control subjects matched for gender, age and body mass index (BMI). In addition, the inflammatory effect of IL-6 on peripheral blood mononuclear cells was measured. RESULTS: Compared to controls, hyperhomocysteinemic subjects have elevated serum levels of CRP and IL-6 (p < or =0.001 and p < 0.005, respectively). Importantly, this raised level of IL-6 was also seen in hyperhomocysteinemic individuals without accompanying hypercholesterolemia or cardiovascular disease. IL-6 increased the release of monocyte chemoattractant protein-1 from peripheral blood mononuclear cells, with particularly enhancing effects in cells from patients with hyperhomocysteinemia. CONCLUSIONS: These data suggest that enhanced inflammation may be associated with homocysteine-related cardiovascular disease, possibly involving IL-6-related mechanisms.
OBJECTIVE: Elevated plasma homocysteine concentration is considered to be an independent risk factor for cardiovascular disease. However, the mechanisms by which hyperhomocysteinemia are related to vascular disease are unclear. High-sensitivity C-reactive protein (CRP), a marker of inflammation, has been reported to be an independent predictor of future myocardial infarction among clinically healthy individuals. Interleukin (IL)-6 is a regulator of CRP and has a key role in initiation of inflammation. The aim of this study was to investigate whether individuals with increased plasma homocysteine concentrations have altered levels of serum CRP and IL-6. MATERIAL AND METHODS: Serum concentrations of CRP and IL-6 were measured in 39 individuals with hyperhomocysteinemia and in 39 control subjects matched for gender, age and body mass index (BMI). In addition, the inflammatory effect of IL-6 on peripheral blood mononuclear cells was measured. RESULTS: Compared to controls, hyperhomocysteinemic subjects have elevated serum levels of CRP and IL-6 (p < or =0.001 and p < 0.005, respectively). Importantly, this raised level of IL-6 was also seen in hyperhomocysteinemic individuals without accompanying hypercholesterolemia or cardiovascular disease. IL-6 increased the release of monocyte chemoattractant protein-1 from peripheral blood mononuclear cells, with particularly enhancing effects in cells from patients with hyperhomocysteinemia. CONCLUSIONS: These data suggest that enhanced inflammation may be associated with homocysteine-related cardiovascular disease, possibly involving IL-6-related mechanisms.
Authors: Bruce E Maryanoff; John C O'Neill; David F McComsey; Stephen C Yabut; Diane K Luci; Alfonzo D Jordan; John A Masucci; William J Jones; Marta C Abad; Alan C Gibbs; Ioanna Petrounia Journal: ACS Med Chem Lett Date: 2011-04-18 Impact factor: 4.345
Authors: Emilene B S Scherer; Samanta O Loureiro; Fernanda C Vuaden; Aline A da Cunha; Felipe Schmitz; Janaína Kolling; Luiz Eduardo B Savio; Maurício R Bogo; Carla D Bonan; Carlos A Netto; Angela T S Wyse Journal: Mol Neurobiol Date: 2014-03-05 Impact factor: 5.590
Authors: Daniella de S Moreira; Paula W Figueiró; Cassiana Siebert; Caroline A Prezzi; Francieli Rohden; Fatima C R Guma; Vanusa Manfredini; Angela T S Wyse Journal: Neurotox Res Date: 2017-12-14 Impact factor: 3.911